Loading…
Indian subsidiary of Colgate-Palmolive, dominant in oral care (toothpaste, toothbrushes) with a leading market share.
Indian subsidiary of Colgate-Palmolive, dominant in oral care (toothpaste, toothbrushes) with a leading market share.
Sells toothpaste, by far its largest product, through distributors who supply small shops across India including rural areas. The US parent owns a majority and is paid royalties for the brand and technology, a recurring cost.
In one line: Indian listed arm of Colgate-Palmolive.
Moat: wide (brand, distribution, installed base). Decades-long dominant market share in Indian oral care, deeply embedded in retail and rural distribution.
Headquarters: Mumbai, India · Founded: 1937 · Employees: 5,127
Size Colgate-Palmolive (India) (COLPAL.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $4.83B, the 214th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,679 on 6 Nov 2026.
Performance Over six months the shares fell 22.5%, against -1.7% for the median peer and 0.0% for the India market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 8.7% over the last twelve months (peer median +5.6%); the operating margin is 27.6% (peer median 12.4%).
Valuation It trades at 32.2× forward earnings against a peer median of 19.9× (6th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 13 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹63.9B | ₹60.4B | ₹60.4B | ₹56.8B | ₹52.3B |
| Revenue growth | — | 0% | +6% | +9% | — |
| Gross profit | ₹38.2B | ₹32.5B | ₹32.9B | ₹30.9B | ₹26.1B |
| EBITDA | ₹19.1B | ₹19.1B | ₹19.9B | ₹19.3B | ₹15.7B |
| Net income | ₹13.6B | ₹13.3B | ₹14.4B | ₹13.2B | ₹10.5B |
| Free cash flow | n/a | ₹17.9B | ₹13.9B | ₹11.9B | ₹11.4B |
| Capital expenditure | n/a | ₹765M | ₹714M | ₹756M | ₹701M |
| Total debt | ₹487M | ₹474M | ₹608M | ₹717M | ₹690M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Colgate-Palmolive (India) COLPAL.NS | $4.83B | -23% | +9% | 28% | 32.2× | 30.8% |
| Hindustan Unilever HINDUNILVR.NS | $49.6B | -12% | +6% | 21% | 41.5× | 27.2% |
| Dabur India DABUR.NS | $7.13B | -19% | +9% | 15% | 32.1× | 27.3% |
| Haleon HLN.L | $40.1B | +1% | +1% | 23% | 16.3× | 4.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COLPAL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | +1.0% | 5th lowest of 21 |
| 6-month return | -22.5% | -1.7% | 4th lowest of 21 |
| Distance from 52-week high | -27.1% | -21.9% | 9th lowest of 21 |
| Revenue growth (TTM) | +8.7% | +5.6% | 9th highest of 21 |
| Operating margin | 27.6% | 12.4% | 5th highest of 21 |
| Forward P/E | 32.2× | 19.9× | 6th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 30.8% | 4.0% | 2nd most demanding of 20 |
| Growth delivered (Del g) | +4.5% | +6.6% | 9th lowest of 20 |
| Hurdle (Req g minus delivered) | +26.3 pp | -2.8 pp | most demanding of 20 |
| EV / EBITDA | 23.1× | 15.9× | 6th most expensive of 15 |
| Net debt / EBITDA | -0.8× | -0.3× | 6th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Colgate-Palmolive (India) COLPAL.NS | India | $4.83B | -23% | +9% | 28% | 32.2× | 30.8% | +4.5% |
| Cupid CUPID.NS | India | $4.83B | +158% | +122% | 34% | n/a | n/a | n/a |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.92B | -28% | +32% | 31% | 15.0× | 4.7% | +41.1% |
| Reynolds Consumer Products REYN | United States | $5.08B | +10% | +2% | 14% | 14.6× | -0.2% | +2.7% |
| Interparfums IPAR | United States | $4.34B | +43% | +3% | 17% | 29.0× | 10.9% | +22.5% |
| Rohto Pharmaceutical 4527.T | Japan | $3.97B | +17% | +10% | 12% | 16.7× | -2.1% | +13.7% |
| Amorepacific 090430.KS | South Korea | $6.03B | -1% | +10% | 9% | 23.8× | 4.0% | -0.8% |
| Coty COTY | United States | $3.57B | +64% | -1% | 5% | 13.3× | 11.3% | +4.6% |
| e.l.f. Beauty ELF | United States | $6.85B | +91% | +31% | 12% | 35.4× | 27.9% | +38.8% |
| APR 278470.KS | South Korea | $7.04B | -40% | +119% | 23% | 17.4× | -1.4% | +47.3% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.29B | +20% | +4% | 6% | 50.2× | 17.6% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.28B | -16% | +2% | 11% | 9.1× | -8.8% | -0.1% |
| Dabur India DABUR.NS | India | $7.13B | -19% | +9% | 15% | 32.1× | 27.3% | +6.6% |
| Lion 4912.T | Japan | $3.19B | +21% | +6% | 8% | 19.9× | -2.4% | +3.5% |
| Proya Cosmetics 603605.SS | China | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% | +23.1% |
| Giant Biogene 2367.HK | Hong Kong | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% | +34.9% |
| Winner Medical 300888.SZ | China | $2.69B | -2% | +4% | 11% | 20.9× | -4.3% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% | +13.0% |
| LG H&h 051900.KS | South Korea | $2.56B | -8% | -3% | 3% | 18.5× | -0.1% | -4.1% |
| Godrej Consumer Products GODREJCP.NS | India | $9.19B | -18% | +12% | 18% | 37.0× | 31.7% | +6.6% |
| Shiseido 4911.T | Japan | $9.52B | +20% | +5% | 4% | 32.8× | 17.5% | +1.0% |